# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced th...
Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a fo...
Wojcicki currently owns shares constituting more than 20% of the total outstanding shares and entitling her to approximately 49...